Company intelligence / Profile preview

DayaCann

Chile

Ownership: Private
Development stage: Other

Overview

DayaCann was a Chile-based medical cannabis joint venture between Fundacion Daya and AusCann focused on cultivation and production of cannabis for medical formulations; it was later acquired by Khiron Life Sciences to support clinical trials and commercialization of medical cannabis products in Chile.[2][5][7][8]

Therapeutic areas: NeurologyOther
Modalities: Plant-derived extractSmall molecule
Industry: Biotech

Partnerships

Fundacion DayaAusCann Group HoldingsKhiron Life Sciences

Beyond the preview

Go deeper on DayaCann.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DayaCann.

Explore the full profile